Roche Stock Has More Upside
- Monday, March 21, 2022, 7:17
- Market
- Add a comment
The stock price of Roche’s ADR has seen a fall of 7% year-to-date, while it’s up 3.5% in a month. Roche’s revenue grew 13% y-o-y to $72.4 billion in 2021, aided by Covid-19 diagnostics tests and Ronapreve – a treatment for Covid-19, developed by Regeneron and distributed by Roche outside the U.S…
About the Author
admin123 has written 23421 stories on this site.
